Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Midori Shimada

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Thoracic Cancer|November 25, 2021
Onset of pulmonary Epstein-Barr virus-positive diffuse large B-cell lymphoma in a patient with silicosisRyosuke Ogata, Hiroshi Soda, Yasuhiro Tanaka, et al.
Cancer Chemotherapy and Pharmacology|September 6, 2019
Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancerMidori Shimada, Hiroyuki Yamaguchi, Minoru Fukuda, et al.
Cancer Chemotherapy and Pharmacology|July 19, 2014
A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancerTakaya Ikeda, Minoru Fukuda, Yoichi Nakamura, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201)Minoru Fukuda, Takeshi Kitazaki, Daiki Ogawara, et al.
The EMBO Journal|September 14, 2010
Cooperative functions of Chk1 and Chk2 reduce tumour susceptibility in vivoHiroyuki Niida, Kazuhiro Murata, Midori Shimada, et al.
Cell Stem Cell|May 7, 2016
Activation of Endogenous Retroviruses in Dnmt1(-/-) ESCs Involves Disruption of SETDB1-Mediated Repression by NP95 Binding to Hemimethylated DNAJafar Sharif, Takaho A Endo, Manabu Nakayama, et al.
Journal of Clinical Medicine|September 28, 2021
Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating FactorYosuke Dotsu, Hiroyuki Yamaguchi, Minoru Fukuda, et al.
Thoracic Cancer|July 17, 2019
Phase II study of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancerHirokazu Taniguchi, Hiroyuki Yamaguchi, Yosuke Dotsu, et al.
Translational Lung Cancer Research|May 17, 2023
Genetic profile of thymic epithelial tumors in the Japanese population: an exploratory study examining potential therapeutic targetsMidori Shimada, Hirokazu Taniguchi, Hiroyuki Yamaguchi, et al.
Thoracic Cancer|September 7, 2023
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO studyHiromi Tomono, Hirokazu Taniguchi, Minoru Fukuda, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Thoracic Cancer|November 25, 2021
Onset of pulmonary Epstein-Barr virus-positive diffuse large B-cell lymphoma in a patient with silicosisRyosuke Ogata, Hiroshi Soda, Yasuhiro Tanaka, et al.
Cancer Chemotherapy and Pharmacology|September 6, 2019
Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancerMidori Shimada, Hiroyuki Yamaguchi, Minoru Fukuda, et al.
Cancer Chemotherapy and Pharmacology|July 19, 2014
A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancerTakaya Ikeda, Minoru Fukuda, Yoichi Nakamura, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201)Minoru Fukuda, Takeshi Kitazaki, Daiki Ogawara, et al.
The EMBO Journal|September 14, 2010
Cooperative functions of Chk1 and Chk2 reduce tumour susceptibility in vivoHiroyuki Niida, Kazuhiro Murata, Midori Shimada, et al.
Cell Stem Cell|May 7, 2016
Activation of Endogenous Retroviruses in Dnmt1(-/-) ESCs Involves Disruption of SETDB1-Mediated Repression by NP95 Binding to Hemimethylated DNAJafar Sharif, Takaho A Endo, Manabu Nakayama, et al.
Journal of Clinical Medicine|September 28, 2021
Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating FactorYosuke Dotsu, Hiroyuki Yamaguchi, Minoru Fukuda, et al.
Thoracic Cancer|July 17, 2019
Phase II study of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancerHirokazu Taniguchi, Hiroyuki Yamaguchi, Yosuke Dotsu, et al.
Translational Lung Cancer Research|May 17, 2023
Genetic profile of thymic epithelial tumors in the Japanese population: an exploratory study examining potential therapeutic targetsMidori Shimada, Hirokazu Taniguchi, Hiroyuki Yamaguchi, et al.
Thoracic Cancer|September 7, 2023
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO studyHiromi Tomono, Hirokazu Taniguchi, Minoru Fukuda, et al.
Pageof 8